IRB #

STUDY00019388

Title

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to study the safety and efficacy (how well it works) of cabozantinib at different dose levels combined with atezolizumab in treating patients with a variety of cancer types.

Medical Condition(s)

Urothelial carcinoma (includes cancer of the bladder, urethra, ureter, and renal pelvis), renal cell carcinoma (kidney cancer), castration-resistant prostate cancer (CRPC), non-squamous non-small cell lung cancer(NSCLC), triple negative breast cancer(TNBC), ovarian cancer(OC), endometrial cancer(EC), hepatocellular cancer(HCC), gastric/gastroesophageal junction cancer(GC/GEJC), colorectal cancer(CRC), head and neck (H&N)cancer, or differentiated thyroid cancer(DTC).

Eligibility Criteria

Male and Female subjects at least 18 years of age.
Cancer diagnosis of one of the above cancers.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You may receive study treatment as long as your cancer does not get worse, you do not have medically unacceptable side effects, and your study doctor judges your condition to be appropriate for this study.

Minors Included

No

Contact

Knight Clinical Trial Information
503-494-1080
trials@ohsu.edu

Sponsor

Exelixis, Inc.

Recruitment End

12/31/2020

Compensation Provided

No


Go Back